Allogeneic Platelet-Rich Plasma: At the Dawn of an Off-the-Shelf Therapy?

Eduardo Anitua; Roberto Prado; Gorka Orive

doi:10.1016/j.tibtech.2016.11.001

Allogeneic Platelet-Rich Plasma: At the Dawn of an Off-the-Shelf Therapy?

Trends Biotechnol. 2017 Feb;35(2):91-93. doi: 10.1016/j.tibtech.2016.11.001. Epub 2016 Nov 28.

Authors

Eduardo Anitua¹, Roberto Prado², Gorka Orive³

Affiliations

¹ Eduardo Anitua Foundation for Biomedical Research, Vitoria, Spain; BTI-Biotechnology Institute, Vitoria, Spain.
² BTI-Biotechnology Institute, Vitoria, Spain.
³ Eduardo Anitua Foundation for Biomedical Research, Vitoria, Spain; BTI-Biotechnology Institute, Vitoria, Spain; Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (EHU), Vitoria, Spain; Networking Biomedical Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), SLFPB-EHU, Vitoria, Spain. Electronic address: gorka.orive@ehu.es.

PMID: 27908451
DOI: 10.1016/j.tibtech.2016.11.001

Abstract

A new therapeutic tool is emerging based on a biomimetic strategy: platelet-rich plasma (PRP) technology. Allogeneic off-the-shelf PRP represents a safe and cost-effective treatment for osteoarthritis and related diseases. This breakthrough opens the door not only to improved treatments and opportunities but also to new challenges with multiple uncertainties.

MeSH terms

Blood Substitutes / chemistry*
Blood Substitutes / therapeutic use*
Humans
Osteoarthritis / blood
Osteoarthritis / therapy*
Platelet-Rich Plasma / chemistry*
Platelet-Rich Plasma / metabolism*
Transplantation, Homologous / methods*

Substances

Blood Substitutes